Comment Ripple Therapeutics to consider $75m-plus IPO in 2023, or Series B, post Phase II trial data, says CEO Sean Rai-Roche
Comment Covid-19 Phase III trial of Eiger’s interferon to start pending ongoing $10m financing, primary investigator says Reynald Castañeda
Uncategorised Civitas Therapeutics receives $38m in financing to further develop inhaled Parkinson’s drug admin